In 2004, in the United States, there were 72 million presentations with a primary diagnosis of a digestive disease and 104 million presentations with combined gastrointestinal (GI) tract diseases and other diseases ( Table 1) . 1 It was also found that those who are older tend to have more GI problems, there was no difference in the rates of digestive disease between the African Americans and the whites, and women were 20% more likely to present than men with digestive diseases. Thus, more than one-third (35%) of all presentations are for digestive diseases. In 2009, in the United States, the cancer statistics revealed 275,720 new cases of GI cancer, with colorectal and pancreatic cancer in the top 10 for both men and women. 2 There were 135,830 deaths due to GI cancer, with colorectal, pancreatic, hepatic, and esophageal cancers in the top 10 for both men and women, except for esophageal cancer, which was only listed for men ( Fig. 1) . 2 Furthermore, 2 of these 3 cancers that have an increasing mortality were GI tract cancers for both genders, with esophageal and hepatic cancers among men and pancreatic and hepatic cancers among women. Worldwide the rates of digestive diseases are staggering.
prevalence were observed for certain GI tract diseases, including gastroesophageal reflux disease (GERD) with an increase of 376 per 100,000 population, hepatitis C with 79 per 100,000 population, chronic constipation with 62 per 100,000 population, intestinal infections with 41 per 100,000 population, and pancreatitis with 23 per 100,000 population. 1 The prevalence of digestive diseases around the world is enormous and varies from country to country ( Table 2) . Worldwide there has been a dynamic shift in the epidemiology of GI tract diseases, with some diseases such as peptic ulcer decreasing dramatically since the discovery of Helicobacter pylori infection and a larger number of conditions increasing, such as GERD, nonalcoholic fatty liver disease, diverticular disease, Barrett esophagus, cholelithiasis, alcoholic liver disease, hepatitis C, chronic pancreatitis, esophageal cancer and colorectal cancer. [3] [4] [5] [6] [7] [8] In conjunction with this increasing incidence of digestive diseases are the re-emergence of certain infectious agents (Box 1) (eg, cholera) and the identification of new agents (eg, H pylori, Laribacter, Campylobacter concisus), which are associated with GI tract diseases. 9 Since the discovery of H pylori there has been an enormous interest in the relationship between microorganisms and GI tract diseases, including cancers.
CAUSE-AND-EFFECT ISSUES
One of the main issues associated with infections and disease is determining the relationship of the cause and effect. The landmark article by Sir Austin Bradford Hill in 1965 titled The environment and disease: association or causation? became widely known as the Bradford Hill's criteria. 10 There were 8 criteria that were required to be met to determine a cause-and-effect relationship (Box 2). It is usually difficult to meet all these criteria, particularly when trying to find the cause-and-effect relationships between organisms in the small intestine or colon because of the large number of organisms living in these environments. Even for H pylori infection and the relationship with gastric cancer, although it is currently the only bacterium classified as a class I carcinogen, the evidence supporting this relationship is not complete in terms of Bradford Hill's criteria.
ORGANISMS ASSOCIATED WITH GI TRACT DISEASES
There are a large number of organisms believed to be responsible for diseases of the digestive system. Some of these organisms are true pathogens, whereas others are merely commensal in nature and are unlikely to ever produce any pathologic condition. Table 3 shows the various types of microbes that are associated with diseases of the GI tract covered in this issue; it is by no means all-inclusive but provides the current magnitude of an ever-increasing field of research. At present, some of these diseases are only associated with a single group of organisms (eg, irritable bowel syndrome), whereas other diseases are affected by all groups of organisms (eg, appendicitis).
FUTURE CHALLENGES
There are a variety of methodological and technical issues related to infectious agents and their role in digestive diseases. For diseases of the colon, the major limitation remains the inability to completely identify these organisms. Identification of bacteria was mainly conducted using culture-based methods. Now, the focus in identification of bacteria is increasingly based on using molecular techniques. Many of these techniques allow the detection and identification of viable but nonculturable cells that are metabolically active but not reproducing. Gene sequencing using single-stranded RNA has been a key method in being able to elucidate multitudes of organisms that remain unknown. At present, there are approximately 9000 bacterial species, and this number is estimated as just the tip of the iceberg. The development of molecular Studies of the emergence and/or spread of antimicrobial resistance genes within pathogen populations methods offers great promise not only in research and development but also in the diagnostic setting (eg, stool samples) ( Table 4) . 11, 12 Clearly, metagenomics, in which genetic material is directly retrieved from environmental sources, will play a critical role in the future development of determining infectious agents of the GI tract. The use of high-throughput technology has already produced important findings in relation to the GI tract microflora, including the differences between adults and children, with numerous uncultured organisms being the crux of the normal human adult gut flora which remain stable but other organisms change depending on environmental and genetic factors, whereas in infants there appear to be a constant transformation of organisms over time ( Figs. 3 and 4) . 11 There have been several new detection methods developed, with some of these using nanoscale electrochemical detectors and others using DNA sensors (extrachromosomal DNA). 13 The use of stable-isotope probing is also being investigated, but even this technique has limitations. 14 Although these technologies are increasing the understanding of the gut microflora, there remains large gaps of knowledge regarding the metabolic functions of these organisms and the relationship they have with human GI disease. These will be extremely fruitful areas of research and development in the coming years.
Infections Associated with GI Tract Diseases

Studies of the emergence and/or spread of antimicrobial-resistant pathogens in human populations
Research on therapeutic approaches that target resistance mechanisms Modification of existing antimicrobials to overcome emergent resistance Antimicrobial research, as related to engineered threats and naturally occurring drugresistant pathogens, focused on the development of broad-spectrum antimicrobials Innate immunity, defined as the study of nonadaptive immune mechanisms that recognize, and respond to, microorganisms, microbial products, and antigens
Coccidioides immitis
Coccidioides posadasii
Box 2 Bradford Hill's criteria for causality
Consistency: The association is consistent when results are replicated in studies in different settings using different methods.
Strength: This is defined by the size of the risk as measured by appropriate statistical tests.
Specificity: This is established when a single putative cause produces a specific effect.
Dose-response relationship: An increasing level of exposure (in amount and/or time) increases the risk.
Temporal relationship: Exposure always precedes the outcome.
Biologic plausibility: The association agrees with currently accepted understanding of pathobiologic processes. This criterion should be applied with caution.
Coherence: The association should be compatible with existing theory and knowledge.
Experiment: The condition can be altered by an appropriate experimental regimen. Experiment is possibly the most important support for a causal relationship. 
